Материал: Дерматовенерология (2015)

8.

Kaufmann R., Bibby A., Bissonnette R. et al. A new calcipotriol/betametha-

sone dipropionate formulation (DaivobetTM) is an effective once-daily treat-

ment for psoriasis vulgaris. Dermatology 2002; 205: 389—393.

9.

Koo J., Cuffie C. A., Tanner D. J. et al. Mometasone furoate 0.1%-salicylic

acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment

of moderate-to-severe psoriasis: a multicenter study. Clin Ther 1998; 20 (2):

283—291.

10.

Lowe N., Feldman S. R., Sherer D. et al. Clobetasol propionate lotion, an ef-

ficient and safe alternative to clobetasol propionate emollient cream in subjects

with moderate to severe plaque-type psoriasis. J Dermatolog Treat 2005; 16:

158—164.

11.

Papp K. A., Guenther L., Boyden B. et al. Early onset of action and efficacy of

a combination of calcipotriene and betamethasone dipropionate in the treat-

ment of psoriasis. J Am Acad Dermatol 2003; 48: 48—54.

12.

Jarratt M. T., Clark S. D., Savin R. C. et al. Evaluation of the efficacy and

safety of clobetasol propionate spray in the treatment of plaque type psoriasis.

Cutis 2006; 78: 348—354.

13.

Douglas W. S., Poulin Y., Decroix J. et al. A new calcipotriol/betamethasone

formulation with rapid onset of action was superior to monotherapy with be-

tamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Ve-

nereol 2002; 82: 131—135.

14.

Guenther L., van de Kerkhof P. C., Snellman E. et al. Efficacy and safety of

a new combination of calcipotriol and betamethasone dipropionate (once or

twice daily) compared to calcipotriol (twice daily) in the treatment of pso-

riasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial.

Br J Dermatol 2002; 147:316—323.

15.

Kragballe K., Noerrelund K. L., Lui H. et al. Efficacy of once-daily treatment

regimens with calcipotriol/betamethasone dipropionate ointment and calci-

potriol ointment in psoriasis vulgaris. Br J Dermatol 2004; 150: 1167—1173.

16.

Ortonne P., Kaufmann R., Lecha M., Goodfield M. Efficacy of treatment

with calcipotriol/betamethasone dipropionate followed by calcipotriol alone

compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised,

double-blind trial. Dermatology 2004; 209: 308—313.

17.

Костинский Г. Б., Кубанов А. А., Петровский Ф. И. Лечение легкого

и средне-тяжелого папулезно-бляшечного псориаза активированным

кожи

пиритионом цинка («Скин-кап») и качество жизни пациентов. Україн-

ський журнал дерматології, венерології, косметології 2012; 46 (3): 49—52.

18.

Sadeghian G., Ziaei H., Nilforoushzadeh M. A. Treatment of localized pso-

Болезни

riasis with a topical formulation of zinc pyrithione. Acta Dermatovenerol Alp

19.

Coven T. R., Burack L. H., Gilleaudeau R. et al. Narrowband UV-B produces

superior clinical and histopathological resolution of moderate-to-severe pso-

riasis in patients compared with broadband UV-B. Arch Dermatol 1997; 133:

1514—1522.

20.

Snellman E., Klimenko T., Rantanen T. Randomized half-side comparison of

narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoria-

sis. Acta Derm Venereol 2004; 84: 132—137.

21.

Bagel J. LCD plus NB-UVB reduces time to improvement of psoriasis vs NB-

UVB alone. J Drugs Dermatol 2009; 8 (4): 351—357.

22.

De Leeuw J., Van Lingen R. G., Both H. et al. A comparative study on the

efficacy of treatment with 585 nm pulsed dye laser and ultraviolet BTL01 in

plaque type psoriasis. Dermatol Surg 2009; 35: 80—91.

23.

Leenutaphong V., Nimkulrat P., Sudtim S. Comparison of phototherapy two

times and four times a week with low doses of narrow-band ultraviolet B in

Asian patients with psoriasis. Photodermatol Photoimmunol Photomed 2000;

16 (5): 202—206.

24.

Yones S. S., Palmer R. A., Garibaldinos T. T. et al. Randomized double-blind

trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A

therapy vs narrowband UV-B therapy. Arch Dermatol 2006; 142: 836—842.

25.

Goldinger S. M., Dummer R., Schmid P. et al. Excimer laser versus narrow-

band UVB (311 nm) in the treatment of psoriasis vulgaris. Dermatology 2006;

213 (2):134—139.

26.

Kaur M., Oliver B., H. J., Feldman S. R. Nonlaser UVB-targeted photothera-

py treatment of psoriasis. Cutis 2006; 78: 200—203.

27.

Grundmann-Kollmann M., Ludwig R., Zollner T. M. et al. Narrowband UVB

and cream psoralen-UVA combination therapy for plaque-type psoriasis.

J Am Acad Dermatol 2004; 50: 734—739.

28.

Олисова О. Ю., Владимиров В. В., Смирнов К. В. и др. Сравнительная

эффективность узкополосной УФБ-терапии 311 нм при псориазе.

Российский журнал кожных и венерических болезней 2011; 1: 36—40.

29.

Housman T. S., Pearce D. J., Feldman S. R. A maintenance protocol for pso-

riasis plaques cleared by the 308 nm excimer laser. J Dermatolog Treat 2004;

15: 94—97.

30.

Katugampola G. A., Rees A. M., Lanigan S. W. Laser treatment of psoriasis.

Br J Dermatol. 1995; 133: 909—913.

31.

Trehan M., Taylor C. R. Medium-dose 308-nm excimer laser for the treat-

ment of psoriasis. J Am Acad Dermatol 2002; 47: 701—708.

32.

Feldman S. R., Mellen B. G., Housman T. S. et al. Efficacy of the 308-nm ex-

Псориаз

Dermatol 2002; 46: 900—906.

cimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad

33.

Kirby B., Buckley D. A., Rogers S. Large increments in psoralen-ultraviolet

A (PUVA) therapy are unsuitable for fair-skinned individuals with psoriasis.

Br J Dermatol. 1999; 140: 661—666.

34.

Buckley D. A., Healy E., Rogers S. A comparison of twice weekly MPD-PU-

VA and three times-weekly skin typing-PUVA regimens for the treatment of

psoriasis. Br J Dermatol 1995; 133 (3): 417—422.

35.

Berg M., Ros A. M. Treatment of psoriasis with psoralens and ultraviolet A.

A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.

Photodermatol Photoimmunol Photomed 1994; 10 (5): 217—220.

36.

Cooper E. J., Herd R. M., Priestley G. C., Hunter J. A. A comparison of bath

water and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque pso-

riasis. Clin Exp Dermatol 2000; 25 (2): 111—114.

37.

Amornpinyokeit N., Asawanonda P. 8-Methoxypsoralen cream plus targeted

narrowband ultraviolet B for psoriasis. Photodermatol Photoimmunol Pho-

tomed 2006; 22: 285—289.

38.

Asawanonda P., Amornpinyokeit N., Nimnuan C. Topical 8-methoxypso-

ralen enhances the therapeutic results of targeted narrowband ultraviolet B

phototherapy for plaque-type psoriasis. J Eur Acad Dermatol Venereol 2008;

22: 50—55.

39.

Schiener R., Brockow T,. Franke A. et al. Bath PUVA and saltwater baths fol-

lowed by UV-B phototherapy as treatments for psoriasis: a randomized con-

trolled trial. Arch Dermatol 2007; 143: 586—596.

40.

Collins P., Rogers S. Bath-water compared with oral delivery of 8-methoxy-

psoralen PUVA therapy for chronic plaque psoriasis. Br J Dermatol 1992; 127

(4): 392—395.

41.

Calzavara-Pinton P. G., Ortel B., Honigsmann H. et al. Safety and effective-

ness of an aggressive and individualized bath-PUVA regimen in the treatment

of psoriasis. Dermatology 1994; 189: 256—259.

42.

Vongthongsri R., Konschitzky R., Seeber A. et al. Randomized, double-blind

comparison of 1 mg/L versus 5 mg/L methoxsalen bath-PUVA therapy for

chronic plaque-type psoriasis. J Am Acad Dermatol 2006; 55 (4): 627—631.

43.

Волнухин В. А., Самсонов В. А., Кравцова И. В. и др. Эффективность

лечения больных псориазом ПУВА-ваннами. Вестник дерматологии

и венерологии 2006; 5: 56—61.

44.

Morison W. L., Baughman R. D., Day R. M. et al. Consensus workshop on the

toxic effects of long-term PUVA therapy. Arch Dermatol 1998; 134: 595—598.

кожи

45.

Racz E., Prens E. P. Phototherapy and photochemotherapy for psoriasis. Der-

matol Clin 2015; 33: 79—89.

Болезни

46.

Жилова М. Б., Волнухин В. А., Дворников А. С. Клинические проявления­

фотоповреждения кожи при многокурсовой фототерапии больных

псориазом. Вестн дерматол и венерол 2014; 6: 114—120.

47.

Archier E., Devaux S., Castela E. et al. Carcinogenic risks of Psoralen UV-A

Therapy and Narrowband UV-B Therapy in chronic plaque psoriasis: a system-

atic literature review. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 3): 22—31.

48.

Chuang T. Y., Heinrich L. A., Schultz M. D. et al. PUVA and skin cancer: a his-

torical cohort study on 492 patients. J Am Acad Dermatol 1992; 26: 173—177.

49.

Forman A. B., Roenigk H. H. Jr, Caro W. A., Magid M. L. Long-term follow-

up of skin cancer in the PUVA-48 cooperative study. Arch Dermatol 1989; 125:

515—519.

50.

Hearn R. M., Kerr A. C., Rahim K. F. et al. Incidence of skin cancers in 3867

patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol

2008; 159: 931—935.

51.

Lindelof B. Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis:

do the known risks now outweigh the benefits? Drug Saf 1999; 20: 289—297.

52.

Marcil I., Stern R. S. Squamous-cell cancer of the skin in patients given PUVA

and cyclosporin: nested cohort crossover study. Lancet 2001; 358: 1042—1045.

53.

Nijsten T. E., Stern R. S. The increased risk of skin cancer is persistent after

discontinuation of psoralen 1 ultraviolet A: a cohort study. J Invest Dermatol

2003; 121: 252—258.

54.

Murase J. E., Lee E. E., Koo J. Effect of ethnicity on the risk of developing

nonmelanoma skin cancer following long-term PUVA therapy. Int J Dermatol

2005; 44: 1016—1021.

55.

Stern R. S., Lunder E. J. Risk of squamous cell carcinoma and methoxsalen

(psoralen) and UV-A radiation (PUVA): a metaanalysis. Arch Dermatol 1998;

134: 1582—1585.

56.

Stern R. S., Nichols K. T., Vakeva L. H. Malignant melanoma in patients

treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation

(PUVA): the PUVA follow-up study. N Engl J Med 1997; 336: 1041—1045.

57.

Archier E., Devaux S., Castela E. et al. Ocular damage in patients with pso-

riasis treated by Psoralen UV-A therapy or Narrow Band UVB therapy. J Eur

Acad Dermatol Venereol 2012; 26 (Suppl. 3): 32—35.

58.

Nast A., Boehncke W.-H., Mrowietz U. et al. S3 — Guidelines on the treat-

ment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges

2012; 10 (Suppl.2): S1—95.

59.

Revicki D., Willian M. K., Saurat J. H. et al. Impact of adalimumab treatment

on health-related quality of life and other patient-reported outcomes: results

from a 16-week randomized controlled trial in patients with moderate to severe

plaque psoriasis. Br J Dermatol 2008; 158: 549—557.

60.

Saurat J. H., Stingl G., Dubertret L. et al. Efficacy and safety results from the

randomized controlled comparative study of adalimumab vs. methotrexate vs.

Псориаз

(3): 558—566.

placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158